This study evaluates SRF617, a fully human IgG4 antibody that inhibits CD39's ATPase activity. SRF617 enhances T-cell proliferation, dendritic cell maturation, and proinflammatory cytokine release from macrophages. In vivo, SRF617 shows antitumor activity in CD39-expressing xenograft models and modulates immune cell infiltration in the TME.
SRF617 binds to human CD39 with high affinity, inhibiting its ATPase activity. It enhances T-cell proliferation, dendritic cell maturation, and cytokine release from macrophages. In vivo, SRF617 exhibits antitumor activity and modulates immune cell infiltration in the TME.
Human CD39 Knockin mouse model developed to assess SRF617's in vivo efficacy and immunomodulatory effects. This model allowed for the evaluation of SRF617's impact on CD39 expression and immune cell dynamics within the TME.
Cancer immunotherapy, CD39 inhibition, Tumor microenvironment modulation, Immune cell activation
Human CD39 Knockin mouse model, SRF617 antibody treatment, Immune cell profiling, TME analysis
From model design to experimental results
Featured in 600+ scientific articles
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Generated with biopharma partners and in-house
and guaranteed freedom to operate
Models with certified health status from professional breeders in US and Europe
